.mdx

Sakar Healthcare Q4 FY26: Oncology traction shows up in profits, exports still early

Sakar Healthcare ended FY26 with a sharp acceleration in both growth and profitability. In Q4 FY26, consolidated revenue rose 42% year on year to INR 71.10 crore, while EBITDA increased 67% to INR 26.24 crore. The quarter’s EBITDA margin expanded to 37% and PAT rose 91% to INR 11.02 crore, translating into a 16% PAT margin.

For the full year, the company reported consolidated revenue of INR 251.74 crore, up 42% over FY25. EBITDA grew 39% to INR 68.89 crore and PAT grew 74% to INR 30.48 crore. Management linked the improved earnings quality to oncology-led scale-up, better operating leverage, and tighter cost discipline.

A business mix shifting toward oncology

The strategic pivot toward oncology is increasingly visible in the revenue mix. Management stated that oncology contributed around 38% of FY26 revenue, compared with 21% in the prior year. Using the FY26 consolidated revenue base, this implies oncology revenue of about INR 95.66 crore and non-oncology revenue of about INR 156.08 crore for the year.

In Q4 FY26, management disclosed absolute segment numbers as well: oncology revenue was INR 31.46 crore and non-oncology revenue was INR 39.64 crore. While this quarter-specific split should not be treated as a steady-state trend, it helps validate that oncology has become a material business line.

A key nuance is that export oncology is still at an early stage. Management stated that oncology export revenue in Q4 was around INR 0.30 crore. The company expects regulated-market supplies to begin in phases, with Europe likely the initial focus.

The oncology platform: approvals, dossiers, and tech transfer

Sakar’s investor presentation and earnings call positioned oncology as the core growth engine, anchored by its EU-GMP approved Bavla facility with integrated API and finished dosage capabilities. The company highlighted development of 55 oncology molecules and stated that 32 are ready for global launch. It also cited 12 marketing authorizations granted in EU and worldwide.

On the commercial pipeline, management provided multiple operating indicators:

• More than 60 oncology business contracts signed, with over 35 discussions ongoing.
• Out of 250 dossiers shared globally, 125 have been submitted and 12 have received marketing authorizations.
• 21 of 32 developed oncology product dossiers have been shared, with 11 approvals received for specific molecules including Abiraterone, Imatinib, Tamoxifen, Capecitabine, Gemcitabine, Carboplatin, Irinotecan, and Docetaxel.

Technology transfer was highlighted as an important bridge between approvals and volume. Management stated technology transfer projects are ongoing with partners including Accord, Intas, Torrent UK and Germany, Emcure, Glenmark, and Zydus. It also stated that four site variation approvals have been received, two each in the UK and EU.

One of the most discussed items was the Accord-Intas portfolio. Management said this portfolio of oncology products to be manufactured by Sakar represents a potential opportunity of INR 50 crore to INR 100 crore, depending on commercialization strategy across Europe. In the Q and A, management clarified that this estimate is based on partner business plans and is not a binding forecast.

Capacity, margins, and the execution checklist for FY27

Management described the Bavla oncology facility as underutilized today, stating capacity utilization is under 30% (around 29% plus). It projected a rise to around 50% to 55% over the next two years as export volumes and tech transfers scale. Management also stated that the oncology division’s EBITDA margins are expected to remain in the 25% to 30% range over the medium term.

At the same time, the call acknowledged that regulated-market commercialization is not instantaneous. Management explained that initial export supplies require several operational steps including serialization, artwork approvals, commercial purchase orders, logistics alignment, and supply chain readiness. It also stated that first supply lead time can be about 120 to 150 days for stringent markets, which helps explain why oncology export revenue remains small today despite marketing authorizations.

From an API integration perspective, management stated the company has developed around 21 APIs in-house and has submitted four CEPs. It said two CEPs have been received for Gefitinib and Capecitabine, enabling integration for regulated-market exports, while two more CEPs are in process with expectations over the next couple of quarters. It also said five additional APIs have been identified for future CEP submissions based on commercial visibility.

The balance sheet points to a working-capital heavy phase. As of March 2026, inventories increased to INR 70.04 crore from INR 43.59 crore and trade receivables rose to INR 50.08 crore from INR 30.72 crore. Cash and cash equivalents were low at INR 0.26 crore. Cash flow data showed operating cash flow of INR 49.26 crore in FY26, but working capital absorption remained negative.

Takeaways

Sakar Healthcare’s FY26 performance shows that its oncology build-out is starting to translate into consolidated earnings momentum. The mix shift toward oncology is visible, with management reporting a rise to 38% of revenue for FY26. However, export oncology is still in the early innings, and the near-term execution challenge is converting approvals into repeat commercial supplies while managing working capital.

Management’s FY27 commentary remained optimistic, reiterating an aspiration for around 40% growth with oncology as the primary driver. The next few quarters are likely to be judged by three measurable outcomes discussed on the call: growth in dossier approvals, the ramp-up of technology transfer supplies, and a sustained increase in oncology plant utilization from the current sub-30% levels.